Justadabble,
I like your posts and you've called more right than wrong (e.g. the Walyering delays and Colby's performance shares).
But this whole "bully boys", good-guys bad-guys thing you're running with is a little childish and divisive.
This is a commerical decision the management of both companies have to make. Sure, STX have tried to gain some leverage, but in the end, TPD management have to make a commerical decision given the situation they find themselves in.
Remember, we don't actually know what sort of cost overruns there have been, and how little cash TPD have left. It is quite possible, Strike have already paid TPD's share to keep Walyering moving as fast as possible, and TPD now are in arrears and have limited room to maneouvre.
Sure, STX have played a bit of hardball, but TPD would not have entered negotiations after what has happened unless they were in a tight spot, I think (otherwise they would've simply walked away - a logical negotiating tactic give production is around the corner). And if TPD have allowed themselves to get into a tight spot again, that is on them, right? Which begs the question, is a standalone company with the current set of managers the best was to go forward in terms of developing Gurvantes and Condor. Or are those two asset best consolidated into the two operating companies (i.e. Strike and TKM)? With TPD shareholders getting their returns via these companies.
- Forums
- ASX - By Stock
- TPD
- Ann: Trading Halt
Ann: Trading Halt, page-132
-
-
- There are more pages in this discussion • 171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TPD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online